Q-omics provides the consensus-scored ZNF780B profile across patient tissues and cancer cell-line models. ZNF780B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF780B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ZNF780B RNA expression shows 21,509 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where ZNF780B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF780B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF780B survival associations across molecular data types. ZNF780B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF780B RNA expression–survival associations across cancer types. High ZNF780B expression shows unfavorable associations in MESO, LGG, CESC and OV, but favorable associations in HNSC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF780B RNA expression.
This table summarizes ZNF780B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF780B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF780B shows lower tumor expression in KIRC, THCA, UCEC and KIRP and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher ZNF780B RNA expression in normal versus tumor tissue (log2 FC = −0.595, t-test p < 0.001).
This table shows molecular features associated with ZNF780B in patient tissues and cancer cell lines. In patient samples, ZNF780B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF780B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
